DDInter548 DDInter119
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Dienestrol
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
Diethylstilbestrol {u} (Compound) upregulates {v} (Gene) CCP110
Diethylstilbestrol {u} (Compound) downregulates {v} (Gene) RPS4Y1
Diethylstilbestrol (Compound) resembles Ritodrine (Compound)
Diethylstilbestrol (Compound) resembles Dienestrol (Compound)
Diethylstilbestrol (Compound) binds CYP2C8 (Gene)
Diethylstilbestrol (Compound) upregulates CCP110 (Gene)
Diethylstilbestrol (Compound) downregulates RPS4Y1 (Gene)